Syndecan-1 expression in gallbladder cancer and its prognostic significance

European Surgical Research

Volumn 41, Issue 2, 2008, Pages 245-250

  Roh, Y H ^a   Kim, Y H ^a   Choi, H J ^a   Lee, K E ^a   Roh, M S ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Gallbladder cancer, prognosis; Immunohistochemistry; Syndecan 1

Indexed keywords

SYNDECAN 1;

ADULT; ARTICLE; CANCER INVASION; CANCER TISSUE; CLINICAL ARTICLE; FEMALE; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; LYMPH VESSEL; MALE; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL;

EID: 50249086356     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000137667     Document Type: Article

References (26)

1. Parkin DM, Muir CS: Cancer incidence in five continents: comparability and quality of data. IARC Sci Publ 1992;120:45-173.
2. Benoist S, Panis Y, Fagniez PL: Long-term results after curative resection for carcinoma of the gallbladder. French University Association for Surgical Research. Am J Surg 1998;175:118-122.
3. Shirai Y, Tsukada K, Ohtani T, Watanabe H, Hatakeyama K: Hepatic metastases from carcinoma of the gallbladder. Cancer 1995;75:2063-2068.
4. Hamrick RE Jr, Liner FJ, Hastings PR, Cohn I Jr: Primary carcinoma of the gallbladder. Ann Surg 1982;195:270-273.
5. Rodriguez-Boulan E, Nelson WJ: Morphogenesis of the polarized epithelial cell phenotype. Science 1989;245:718-725.
6. Admas JC, Watt FM: Regulation of differentiation and development by extracellular matrix. Development 1993;117:1183-1198.
7. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA: Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-1383.
8. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001;411:375-379.
9. Sanderson RD, Turnbull JE, Gallagher JT, Lander AD: Fine structure of heparan sulfate regulated syndecan-1 function and cell behavior. J Biol Chem 1994;269:13100-13106.
10. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Buchler MW: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 2000;88:12-20.
11. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y: Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997;74:482-491.
12. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, Haglund C: Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 2001;95:1-6.
13. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R: Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol 1997;117:312-315.
14. Inki P, Joensuu H, Grenman R, Klemi P, Jalkanen M: Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 1994;70:319-323.
15. Anttonen A, Heikkila P, Kajanti M, Jalkanen M, Joensuu H: High syndecan-1 expression is associated with favorable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 2001;32:297-305.
16. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C: Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004;67:11-18.
17. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C: High-syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003;98:474-483.
18. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A: Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 2003;43:157-164.
19. Chen CL, Ou DL: Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol 2006;37:1279-1285.
20. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L: Tissue microarray analysis revels prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20-29.
21. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C: Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 2005;68:97-106.
22. Hamilton SR, Alatonen LA: World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of the Digestive System. Lyon, IARC Press, 2004.
23. Greene FL, Page DL, Fleming ID: AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.
24. Kato M, Saunders S, Nguyen H, Bernfield M: Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 1995;6:559-576.
25. Hirabayashi K, Numa F, Suminami Y, Murakami A, Murakami T, Kato H: Altered proliferative and metastatic potential associated with increased expression of syndecan-1. Tumor Biol 1998;19:454-463.
26. Ragnarsson L, Stromberg T, Wijdenes J, Totterman TH, Weigelt C: Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells. Cancer Immunol Immunother 2001;50:382-390.